Thierry Buclin

Publications | Phd and Masters theses

Advanced search is available through Serval

Publications can be managed by accessing Serval via MyUnil


438 publications

In press | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | ...
 
Population pharmacokinetics of dolutegravir: influence of drug-drug interactions in a real-life setting.
Barcelo C., Aouri M., Courlet P., Guidi M., Braun D.L., Günthard H.F., Piso R.J., Cavassini M., Buclin T., Decosterd L.A. et al. The Journal of antimicrobial chemotherapy. Peer-reviewed.
 
Imatinib uptake into cells is not mediated by organic cation transporters OCT1, OCT2, or OCT3, but is influenced by extracellular pH.
Blanc Mettral J., Faller N., Cruchon S., Sottas L., Buclin T., Schild L., Choong E., Nahimana A., Decosterd L.A. Drug metabolism letters. Peer-reviewed.
 
Therapeutic drug monitoring of targeted anticancer protein kinase inhibitors in routine clinical use: A critical review
Cardoso E., Guidi M., Blanchet B., Schneider M.P., Decosterd L.A., Buclin T., Csajka C., Widmer N. Therapeutic drug monitoring. Peer-reviewed.
 
Optimisation of vancomycin exposure in neonates based on the best level of evidence.
Dao K., Guidi M., André P., Giannoni E., Basterrechea S., Zhao W., Fuchs A., Pfister M., Buclin T., Csajka C. Pharmacological research p. 104278. Peer-reviewed.
 
Pharmacokinetic profiles of boosted darunavir, dolutegravir and lamivudine in aging patients enrolled in the Swiss HIV Cohort Study.
Courlet P., Stader F., Guidi M., Saldanha S.A., Stoeckle M., Cavassini M., Battegay M., Buclin T., Decosterd L.A., Marzolini C. et al., 2019/09/03. AIDS. Peer-reviewed.
 
UHPLC-MS/MS assay for simultaneous determination of amlodipine, metoprolol, pravastatin, rosuvastatin, atorvastatin with its active metabolites in human plasma, for population-scale drug-drug interactions studies in people living with HIV.
Courlet P., Spaggiari D., Desfontaine V., Cavassini M., Alves Saldanha S., Buclin T., Marzolini C., Csajka C., Decosterd L.A., 2019/09/01. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 1125 p. 121733. Peer-reviewed.
 
Compassionate Use of Letermovir in a 2-Year-Old Immunocompromised Child With Resistant Cytomegalovirus Disease.
Pérez Marín M., Decosterd L.A., Andre P., Buclin T., Mercier T., Murray K., Rizzi M., Meylan P., Jaton-Ogay P., Opota O. et al., 2019/06/11. Journal of the Pediatric Infectious Diseases Society. Peer-reviewed.
 
Escitalopram population pharmacokinetics in people living with human immunodeficiency virus and in the psychiatric population: Drug-drug interactions and probability of target attainment.
Courlet P., Guidi M., Glatard A., Alves Saldanha S., Cavassini M., Buclin T., Marzolini C., Eap C.B., Decosterd L.A., Csajka C. et al., 2019/05/29. British journal of clinical pharmacology. Peer-reviewed.
 
Clindamycin clearance during Cytosorb<sup>®</sup> hemoadsorption: A case report and pharmacokinetic study.
Poli E.C., Simoni C., André P., Buclin T., Longchamp D., Perez M.H., Ferry T., Schneider A.G., 2019/05. The International journal of artificial organs, 42 (5) pp. 258-262. Peer-reviewed.
Pharmacovigilance, hémovigilance, vaccinovigilance, tératovigilance… : quelles retombées imprévues pour les patients, les intervenants de santé et les systèmes de soins ?
Buclin Thierry, Foley Rose-Anna, Livio Françoise, 2019/04/11. Anthropologie & Santé.
 
Complementary medicine use during cancer treatment and potential herb-drug interactions from a cross-sectional study in an academic centre.
Jermini M., Dubois J., Rodondi P.Y., Zaman K., Buclin T., Csajka C., Orcurto A., E Rothuizen L., 2019/03/25. Scientific reports, 9 (1) p. 5078. Peer-reviewed.
 
Sub-picomolar quantification of PTH 1-34 in plasma by UHPLC-MS/MS after subcutaneous injection of teriparatide and identification of PTH 1-33, its degradation product.
Eugster P.J., Chtioui H., Herren A., Dunand M., Cappelle D., Bourquin J., Buclin T., Grouzmann E., 2019/03/20. Journal of pharmaceutical and biomedical analysis, 166 pp. 205-212. Peer-reviewed.
 
Multicenter Population Pharmacokinetic Study of Colistimethate Sodium and Colistin Dosed as in Normal Renal Function in Patients on Continuous Renal Replacement Therapy.
Leuppi-Taegtmeyer A.B., Decosterd L., Osthoff M., Mueller N.J., Buclin T., Corti N., 2019/02. Antimicrobial agents and chemotherapy, 63 (2). Peer-reviewed.
 
Development and validation of a multiplex UHPLC-MS/MS method for the determination of the investigational antibiotic against multi-resistant tuberculosis macozinone (PBTZ169) and five active metabolites in human plasma.
Spaggiari D., Desfontaine V., Cruchon S., Guinchard S., Vocat A., Blattes E., Pitteloud J., Ciullini L., Bardinet C., Ivanyuk A. et al., 2019. PloS one, 14 (5) pp. e0217139. Peer-reviewed.
Intravenous brivaracetam in status epilepticus: Correlation between loading dose, plasma levels and clinical response.
Aicua-Rapun I., André P., Rossetti A.O., Decosterd L.A., Buclin T., Novy J., 2019/01. Epilepsy research, 149 pp. 88-91. Peer-reviewed.
 
Therapeutic drug monitoring (TDM)
Pascal A., Widmer N., Buclin T., 2019. pp. 1-9 dans Swiss recommendations for adult cystic fibrosis care chap. 4.2.3, RMS Editions/Médecine et Hygiène.
 
Effect of renal clearance and continuous renal replacement therapy on appropriateness of recommended meropenem dosing regimens in critically ill patients with susceptible life-threatening infections.
Burger R., Guidi M., Calpini V., Lamoth F., Decosterd L., Robatel C., Buclin T., Csajka C., Marchetti O., 2018/12/01. The Journal of antimicrobial chemotherapy, 73 (12) pp. 3413-3422. Peer-reviewed.
Levetiracetam circulating concentrations and response in status epilepticus.
Perrenoud M., André P., Buclin T., Decosterd L.A., Rossetti A.O., Novy J., 2018/11. Epilepsy & behavior, 88 pp. 61-65. Peer-reviewed.
 
Myoglobinuria in two patients with Duchenne muscular dystrophy after treatment with zoledronate: a case-report and call for caution.
Ivanyuk A., García Segarra N., Buclin T., Klein A., Jacquier D., Newman C.J., Bloetzer C., 2018/10. Neuromuscular disorders, 28 (10) pp. 865-867. Peer-reviewed.
 
Comparison against current standards of a DNA aptamer for the label-free quantification of tobramycin in human sera employed for therapeutic drug monitoring.
Tenaglia E., Ferretti A., Decosterd L.A., Werner D., Mercier T., Widmer N., Buclin T., Guiducci C., 2018/09/10. Journal of pharmaceutical and biomedical analysis, 159 pp. 341-347. Peer-reviewed.
Efficacy and safety of continuous infusions with elastomeric pumps for outpatient parenteral antimicrobial therapy (OPAT): an observational study.
Voumard R., Gardiol C., André P., Arensdorff L., Cochet C., Boillat-Blanco N., Decosterd L., Buclin T., de Vallière S., 2018/09/01. The Journal of antimicrobial chemotherapy, 73 (9) pp. 2540-2545. Peer-reviewed.
 
Ethical approval for multicenter cohort studies on drug exposure during pregnancy: A survey among members of the European Network of Teratology Information Services (ENTIS).
Winterfeld U., Weber-Schöndorfer C., Schaefer C., von Elm E., Buclin T., 2018/09. Reproductive toxicology, 80 pp. 68-72. Peer-reviewed.
 
Sensitive quantification of the somatostatin analog AP102 in plasma by ultra-high pressure liquid chromatography-tandem mass spectrometry and application to a pharmacokinetic study in rats.
Eugster P.J., Boyle C.N., Prod'hom S., Tarasco E., Buclin T., Lutz T.A., Harris A.G., Grouzmann E., 2018/09. Drug testing and analysis, 10 (9) pp. 1448-1457. Peer-reviewed.
 
Antiepileptika in der Stillzeit : Wie beraten wir die Mütter? [Use of antiepileptic drugs during breastfeeding : What do we tell the mother?]
Crettenand M., Rossetti A.O., Buclin T., Winterfeld U., 2018/08. Der Nervenarzt, 89 (8) pp. 913-921. Peer-reviewed.
 
Association of Patient Sex With Chemotherapy-Related Toxic Effects: A Retrospective Analysis of the PETACC-3 Trial Conducted by the EORTC Gastrointestinal Group.
Cristina V., Mahachie J., Mauer M., Buclin T., Van Cutsem E., Roth A., Wagner A.D., 2018/07/01. JAMA oncology, 4 (7) pp. 1003-1006. Peer-reviewed.
 
LC-MS/MS method for the simultaneous analysis of seven antimalarials and two active metabolites in dried blood spots for applications in field trials: Analytical and clinical validation.
Gallay J., Prod'hom S., Mercier T., Bardinet C., Spaggiari D., Pothin E., Buclin T., Genton B., Decosterd L.A., 2018/05/30. Journal of pharmaceutical and biomedical analysis, 154 pp. 263-277. Peer-reviewed.
 
Quantification of the next-generation oral anti-tumor drugs dabrafenib, trametinib, vemurafenib, cobimetinib, pazopanib, regorafenib and two metabolites in human plasma by liquid chromatography-tandem mass spectrometry.
Cardoso E., Mercier T., Wagner A.D., Homicsko K., Michielin O., Ellefsen-Lavoie K., Cagnon L., Diezi M., Buclin T., Widmer N. et al., 2018/04/15. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 1083 pp. 124-136. Peer-reviewed.
 
Pregnancy outcomes in women on metformin for diabetes or other indications among those seeking teratology information services.
Panchaud A., Rousson V., Vial T., Bernard N., Baud D., Amar E., De Santis M., Pistelli A., Dautriche A., Beau-Salinas F. et al., 2018/03. British journal of clinical pharmacology, 84 (3) pp. 568-578. Peer-reviewed.
N-acetylcysteine in a Double-Blind Randomized Placebo-Controlled Trial: Toward Biomarker-Guided Treatment in Early Psychosis.
Conus P., Seidman L.J., Fournier M., Xin L., Cleusix M., Baumann P.S., Ferrari C., Cousins A., Alameda L., Gholam-Rezaee M. et al., 2018/02/15. Schizophrenia bulletin, 44 (2) pp. 317-327. Peer-reviewed.
 
Methods for Personalised Delivery Rate Computation for Propofol IV Administered Anesthetic
Simalatsar Alena, Guidi Monia, Roduit Pierre, Buclin Thierry, 2018. dans Automated Reasoning for System Biology and Medicine, Springer International Publishing.
 
Free and total plasma concentrations of elvitegravir/cobicistat during pregnancy and postpartum: a case report.
Marzolini C., Decosterd L., Winterfeld U., Tissot F., Francini K., Buclin T., Livio F., 2017/12. British journal of clinical pharmacology, 83 (12) pp. 2835-2838. Peer-reviewed.
Adequate plasma drug concentrations suggest that amoxicillin can be administered by continuous infusion using elastomeric pumps.
Arensdorff L., Boillat-Blanco N., Decosterd L., Buclin T., de Vallière S., 2017/09/01. The Journal of antimicrobial chemotherapy, 72 (9) pp. 2613-2615. Peer-reviewed.
 
Lamotrigine serum levels: Ceiling effect in people with epilepsy in remission?
D'Anto J., Wnuk W., Rossetti A.O., Decosterd L.A., Buclin T., Novy J., 2017/09. Epilepsy & behavior, 74 pp. 41-44. Peer-reviewed.
 
Renal Drug Transporters and Drug Interactions.
Ivanyuk A., Livio F., Biollaz J., Buclin T., 2017/08. Clinical pharmacokinetics, 56 (8) pp. 825-892. Peer-reviewed.
 
Guidance to develop individual dose recommendations for patients on chronic hemodialysis.
Gotta V., Dao K., Rodieux F., Buclin T., Livio F., Pfister M., 2017/07. Expert review of clinical pharmacology, 10 (7) pp. 737-752. Peer-reviewed.
Antibiotic stability related to temperature variations in elastomeric pumps used for outpatient parenteral antimicrobial therapy (OPAT).
Voumard R., Van Neyghem N., Cochet C., Gardiol C., Decosterd L., Buclin T., de Valliere S., 2017/05/01. The Journal of antimicrobial chemotherapy, 72 (5) pp. 1462-1465. Peer-reviewed.
 
N-acetyl-cysteine in a double-blind randomized placebo-controlled trial: Towards biomarker guided treatment in early psychosis
Conus P., Fournier M., Xin L., Baumann P., Ferrari C., Cousins A., Alameda L., Golay P., Jenni R., Kashavan M.S. et al., 2017/04. pp. S806 dans European Psychiatry, Elsevier BV.
 
Pharmacokinetics of Pomalidomide in a Patient Receiving Hemodialysis Using a High-Cutoff Filter.
Dao K., Chtioui H., Lu Y., Peer C.J., Figg W.D., Pruijm M., Buclin T., Kissling S., 2017/04. American journal of kidney diseases, 69 (4) pp. 553-554. Peer-reviewed.
 
Population Pharmacokinetics and Pharmacogenetics Analysis of Rilpivirine in HIV-1-Infected Individuals.
Aouri M., Barcelo C., Guidi M., Rotger M., Cavassini M., Hizrel C., Buclin T., Decosterd L.A., Csajka C., Swiss HIV Cohort Study, 2017/04. Antimicrobial agents and chemotherapy, 61 (1) p. 10. Peer-reviewed.
 
SA19. N-Acetyl-Cysteine in a Double-Blind Randomized Placebo-Controlled Trial: Toward Biomarker-Guided Treatment in Early Psychosis
Do Kim, Seidman Larry J., Fournier Margot, Xin Lijing, Cleusix Martine, Baumann Philipp S., Ferrari Carina, Cousins Ann, Alameda Luis, Gholam-Rezaee Mehdi et al., 2017/03/01. pp. S119-S120 dans Schizophrenia Bulletin, Oxford University Press (OUP).
 
Adverse drug reactions as a cause of admission to intensive care unit: a 4-months prospective cohort study
Berthaut V., Renard D., Schaller M.D., Manzon C., Voirol P., Buclin T., Livio F., 2017., 17th International Society of Pharmacovigilance (ISoP) Annual Meeting, Liverpool p. 944 dans Drug Safety.
 
Direct oral anticoagulants: are they safer than vitamin K antagonists?
Baumberger M., Hugli O., Buclin T., Livio F., 2017., 17th International Society of Pharmacovigilance (ISoP) Annual Meeting, Liverpool pp. 943-944 dans Drug Safety.
 
Pharmacokinetics of lenalidomide during high cut-off dialysis in a patient with multiple myeloma and renal failure.
Dao K., Lu Y., Peer C.J., Figg W.D., Stadelmann R., Burnier M., Buclin T., Kissling S., 2017/01. Cancer chemotherapy and pharmacology, 79 (1) pp. 215-218. Peer-reviewed.
 
The levels of vancomycin in the blood and the wound after the local treatment of bone and soft-tissue infection with antibiotic-loaded calcium sulphate as carrier material.
Wahl P., Guidi M., Benninger E., Rönn K., Gautier E., Buclin T., Magnin J.L., Livio F., 2017. The Bone & Joint Journal, 99-B (11) pp. 1537-1544. Peer-reviewed.
 
Use of Dipeptidyl-Peptidase IV Inhibitors and Bullous Pemphigoid.
Schaffer C., Buclin T., Jornayvaz F.R., Cazzaniga S., Borradori L., Gilliet M., Feldmeyer L., 2017. Dermatology, 233 (5) pp. 401-403. Peer-reviewed.
 
The emerging role of multiplex tandem mass spectrometry analysis for therapeutic drug monitoring and personalized medicine
Decosterd L.A., Widmer N., André P., Aouri M., Buclin T., 2016/11. TrAC Trends in Analytical Chemistry, 84 pp. 5-13. Peer-reviewed.
 
Cascaded PID controller for anaesthesia delivery.
Simalatsar A., Guidi M., Buclin T., 2016/08. Conference proceedings, 2016 pp. 533-536. Peer-reviewed.
 
Comparison of Population Pharmacokinetics Based on Steady-State Assumption Versus Electronically Monitored Adherence to Lopinavir, Atazanavir, Efavirenz, and Etravirine: A Retrospective Study.
Fuchs A., Rotzinger A., Cavassini M., Bugnon O., Buclin T., Schneider M.P., Csajka C., 2016/08. Therapeutic drug monitoring, 38 (4) pp. 506-515. Peer-reviewed.
Biases affecting injected doses of an experimental drug during clinical trials.
Perrottet N., Brunner-Ferber F., Grouzmann E., Spertini F., Biollaz J., Buclin T., Widmer N., 2016/07/16. Trials, 17 (1) p. 321. Peer-reviewed.
 
Population pharmacokinetic analysis of elvitegravir and cobicistat in HIV-1-infected individuals.
Barceló C., Gaspar F., Aouri M., Panchaud A., Rotger M., Guidi M., Cavassini M., Buclin T., Decosterd L.A., Csajka C. et al., 2016/07. The Journal of antimicrobial chemotherapy, 71 (7) pp. 1933-1942. Peer-reviewed.
 
Pregnancy outcome following maternal exposure to pregabalin may call for concern.
Winterfeld U., Merlob P., Baud D., Rousson V., Panchaud A., Rothuizen L.E., Bernard N., Vial T., Yates L.M., Pistelli A. et al., 2016/06/14. Neurology, 86 (24) pp. 2251-2257. Peer-reviewed.
 
Pharmacovigilance [Pharmacovigilance update]
Dao K., Chtioui H., Rothuizen L.E., Diezi L., Prod'hom S., Winterfeld U., Buclin T., Livio F., 2016/01/13. Revue medicale suisse, 12 (500) pp. 75-79.
Gentamicin Exposure and Sensorineural Hearing Loss in Preterm Infants.
Fuchs A., Zimmermann L., Bickle Graz M., Cherpillod J., Tolsa J.F., Buclin T., Giannoni E., 2016. PloS one, 11 (7) pp. e0158806. Peer-reviewed.
 
In Vivo Profiling and Distribution of Known and Novel Phase I and Phase II Metabolites of Efavirenz in Plasma, Urine, and Cerebrospinal Fluid.
Aouri M., Barcelo C., Ternon B., Cavassini M., Anagnostopoulos A., Yerly S., Hugues H., Vernazza P., Günthard H.F., Buclin T. et al., 2016. Drug Metabolism and Disposition: the Biological Fate of Chemicals, 44 (1) pp. 151-161.
 
Multigenerational effects of the anticancer drug tamoxifen and its metabolite 4-hydroxy-tamoxifen on Daphnia pulex.
Borgatta M., Waridel P., Decosterd L.A., Buclin T., Chèvre N., 2016. Science of the Total Environment, 545-546 pp. 21-29.
 
Paracétamol et ibuprofène en pédiatrie : Revue critique des indications, risques et autres points controversés
Dao Kim, Laubscher Bernard, Buclin Thierry, 2016. Paediatrica, 27 (2) pp. 30-34. Peer-reviewed.
 
Pharmacokinetic modelling of dialytic clearance in a case of acyclovir intoxication.
Kissling S., Fuchs A., Gobin N., Vogt B., Burnier M., Decosterd L.A., Buclin T., Livio F., 2015/11. International Journal of Antimicrobial Agents, 45 (3) pp. 325-327. Peer-reviewed.
 
Des doutes insuffisants pour changer nos pratiques
Winterfeld Ursula, Baud David, Panchaud Alice, Rothuizen Laura, Livio Françoise, Stoller Rudolf, Buclin Thierry, 2015/10. Bulletin des médecins suisses, 96 (41) pp. 1494-1495.
 
Suivi thérapeutique pharmacologique des inhibiteurs de protéines kinases
Buclin Thierry, Csajka Chantal, Guiducci Carlotta, Decosterd Laurent A, 2015/09. Innovations & Thérapeutiques en Oncologie, 1 (1) pp. 12-23.
 
Therapeutic drug monitoring of targeted anticancer therapy.
Decosterd L.A., Widmer N., Zaman K., Cardoso E., Buclin T., Csajka C., 2015/09. Biomarkers In Medicine, 9 (9) pp. 887-893. Peer-reviewed.
 
Intermittent hemodialysis treatment in cefepime-induced neurotoxicity: Case report, pharmacokinetic modeling, and review of the literature.
Mani L.Y., Kissling S., Viceic D., Vogt B., Burnier M., Buclin T., Renard D., 2015/07. Hemodialysis International. International Symposium On Home Hemodialysis, 19 (2) pp. 333-343. Peer-reviewed.
 
Multiplex Mass Spectrometry Analysis of Latest-Generation Antiepileptic Drugs: A Clinically Useful Laboratory Tool for Improved Real-Time Patients' Care.
Decosterd LA, Mercier T, André P, Bertholet S, Rothuizen LE, Rossetti AO, Buclin T, 2015/06. Epileptologie, 32 (2) pp. 85-89.
 
Pregnancy outcome following maternal exposure to mirtazapine: a multicenter, prospective study.
Winterfeld U., Klinger G., Panchaud A., Stephens S., Arnon J., Malm H., Te Winkel B., Clementi M., Pistelli A., Maňáková E. et al., 2015/06. Journal of Clinical Psychopharmacology, 35 (3) pp. 250-259. Peer-reviewed.
 
Erlotinib: another candidate for the therapeutic drug monitoring of targeted therapy of cancer? A pharmacokinetic and pharmacodynamic systematic review of literature.
Petit-Jean E., Buclin T., Guidi M., Quoix E., Gourieux B., Decosterd L.A., Gairard-Dory A.C., Ubeaud-Séquier G., Widmer N., 2015. Therapeutic Drug Monitoring, 37 (1) pp. 2-21. Peer-reviewed.
 
Label-free detection of tobramycin in serum by transmission-localized surface plasmon resonance.
Cappi G., Spiga F.M., Moncada Y., Ferretti A., Beyeler M., Bianchessi M., Decosterd L., Buclin T., Guiducci C., 2015. Analytical Chemistry, 87 (10) pp. 5278-5285.
 
Médicaments, grossesse et lactation.
Delaloye J.F., Panchaud A., Weisskopf E., Winterfeld U., Rothuizen L., Vial Y., Csajka C., Buclin T., Hohlfeld P., 2015/01., 4e éd. 252 p, Médecine et Hygiène.
 
Pediatric reference intervals for plasma free and total metanephrines established with a parametric approach: Relevance to the diagnosis of neuroblastoma.
Franscini L.C., Vazquez-Montes M., Buclin T., Perera R., Dunand M., Grouzmann E., Beck-Popovic M., 2015. Pediatric Blood and Cancer, 62 (4) pp. 587-593. Peer-reviewed.
 
Pharmacokinetics in hepatic impairment: Mind the protein binding.
Chtioui H., Buclin T., 2015. Journal of Hepatology, 63 (6) pp. 1539-1540. Peer-reviewed.
 
Pharmacovigilance [Pharmacovigilance update].
Fogarasi Szabo N., Diezi L., Delenclos L., Renard D., Chtioui H., Rothuizen L.E., Buclin T., Livio F., 2015/01. Revue Médicale Suisse, 11 (456-457) pp. 124-128.
 
Population pharmacokinetic study to evaluate dosing strategies of imipenem in neonates and infants
Fuchs A., Giannoni E., Guidi M., Decosterd L.A., Marchetti O., Pfister M., Widmer N., Buclin T., Csajka C., 2015. pp. Abstr. 3505 dans 24th Population Approach Group in Europe (PAGE) Meeting, PAGE. Abstracts of the Annual Meeting of the Population Approach Group in Europe. Peer-reviewed.
 
Population pharmacokinetic study to evaluate dosing strategies of imipenem in neonates and infants
Fuchs A., Giannoni E., Guidi M., Decosterd L.A., Marchetti O., Pfister M., Widmer N., Buclin T., Csajka C., 2015. dans Nano-Tera Annual Plenary Meeting.
 
Setting-up a multi-center human research: Systematic observation during a Swiss clinical trial
Gotta V., Vallotton L., Buclin T., Widmer N., 2015. Bioethica Forum, 8 (1) pp. 25-28. Peer-reviewed.
 
The anticancer drug metabolites endoxifen and 4-hydroxy-tamoxifen induce toxic effects on Daphnia pulex in a two-generation study.
Borgatta M., Decosterd L.A., Waridel P., Buclin T., Chèvre N., 2015. Science of the Total Environment, 520 pp. 232-240.
 
Therapeutic Drug Monitoring of Antiepileptic Drugs in the 21st Century
André P., Novy J., Decosterd LA, Buclin T., Rothuizen LE, 2015/01/01. Epileptologie 32 pp. 78-84.
 
Dysménorrhée: patience, pilules ou bouillotte [Dysmenorrhea: patience, pills or hot-water bottle?].
Graz B., Savoy M., Buclin T., Bonvin E., 2014/11. Revue Médicale Suisse, 10 (452) pp. 2285-2288.
 
Nouveaux traitements de l'hépatite C: aspects pharmacologiques et potentiel d'interaction [New hepatitis C treatments: pharmacological considerations and potential for drug interactions].
Chtioui H., Buclin T., Moradpour D., 2014/09. Revue Médicale Suisse, 10 (440) pp. 1600-4, 1606.
 
Antiepileptika bei Frauen im gebärfähigen Alter und in der Schwangerschaft : Vergleich der Fachinformationen in Deutschland und der Schweiz mit dem aktuellen Wissensstand [Antiepileptics in women of childbearing age and during pregnancy : Comparison of specialized information with the current state of knowledge in Germany and Switzerland].
Winterfeld U., Gotta V., Rothuizen L.E., Panchaud A., Rossetti A.O., Buclin T., 2014. Der Nervenarzt, 85 (6) pp. 738-746. Peer-reviewed.
 
Caractérisation du profil pharmacocinétique de la vancomycine chez des patients hospitalisés en médecine générale et chirurgie
Ribeiro J., Cerruti J., Widmer N., Livio F., Buclin T., Csajka C., Guidi M., 2014. dans 2e Congrès Suisse des Pharmaciens.
 
Clinical usefulness of therapeutic concentration monitoring for imatinib dosage individualization: results from a randomized controlled trial.
Gotta V., Widmer N., Decosterd L.A., Chalandon Y., Heim D., Gregor M., Benz R., Leoncini-Franscini L., Baerlocher G.M., Duchosal M.A. et al., 2014. Cancer Chemotherapy and Pharmacology, 74 (6) pp. 1307-1319. Peer-reviewed.
Dosing regimen of gentamicin in neonates: evaluation of current guidelines based on a large population pharmacokinetic analysis
Fuchs A., Guidi M., Giannoni E., Werner D., Widmer N., Buclin T., Csajka C., 2014. dans ESCIM 2014, European and Swiss Congress of Internal Medicin.
 
EzeCHiel: a story of individualized medicine validation - case of gentamicin dosing regimen optimisation in newborns
Fuchs A., Thoma Y., Sutter Y., Stadelmann J., Csajka C., Guidi M., Buclin T., Widmer N., 2014. dans Nano-Tera Annual Plenary Meeting 2014: Virtual Edition.
 
High-throughput hydrophilic interaction chromatography coupled to tandem mass spectrometry for the optimized quantification of the anti-Gram-negatives antibiotic colistin A/B and its pro-drug colistimethate.
Mercier T., Tissot F., Gardiol C., Corti N., Wehrli S., Guidi M., Csajka C., Buclin T., Couet W., Marchetti O. et al., 2014. Journal of Chromatography. A, 1369 pp. 52-63. Peer-reviewed.
Is HLA-A*3101 screening cost-effective for preventing carbamazepine-induced severe toxidermia?
Decollogny Anne, Pinget Christophe, Rossetti Andrea, Buclin Thierry, Livio Françoise, 2014. dans European and Swiss Congress of Internal Medicine.
 
Large-scale imatinib dose-concentration-effect study in CML patients under routine care conditions.
Gotta V., Bouchet S., Widmer N., Schuld P., Decosterd L.A., Buclin T., Mahon F.X., Csajka C., Molimard M., 2014. Leukemia Research, 38 (7) pp. 764-772. Peer-reviewed.
 
Perampanel: a significant liver enzyme inducer in some patients?
Novy J., Rothuizen L.E., Buclin T., Rossetti A.O., 2014. European Neurology, 72 (3-4) pp. 213-216. Peer-reviewed.
 
Pharmacologie orthopédique
Livio F., Renard D., Senn L., Buclin T., 2014. pp. 35-70 dans Jolles-Haeberli B. (eds.) Manuel Pratique de Chirurgie Orthopédique chap. 2, Elsevier Masson.
Population pharmacokinetic modelling and evaluation of different dosage regimens for darunavir and ritonavir in HIV-infected individuals.
Arab-Alameddine M., Lubomirov R., Fayet-Mello A., Aouri M., Rotger M., Buclin T., Widmer N., Gatri M., Ledergerber B., Rentsch K. et al., 2014. Journal of Antimicrobial Chemotherapy, 69 (9) pp. 2489-2498. Peer-reviewed.
 
Population pharmacokinetic study of gentamicin in a large cohort of premature and term neonates.
Fuchs A., Guidi M., Giannoni E., Werner D., Buclin T., Widmer N., Csajka C., 2014. British Journal of Clinical Pharmacology, 78 (5) pp. 1090-1101. Peer-reviewed.
Tobramycin exposure from active calcium sulfate bone graft substitute.
Livio F., Wahl P., Csajka C., Gautier E., Buclin T., 2014. Bmc Pharmacology and Toxicology, 15 (1) p. 12. Peer-reviewed.
 
Towards a new combination therapy for tuberculosis with next generation benzothiazinones.
Makarov V., Lechartier B., Zhang M., Neres J., van der Sar A.M., Raadsen S.A., Hartkoorn R.C., Ryabova O.B., Vocat A., Decosterd L.A. et al., 2014. Embo Molecular Medicine, 6 (3) pp. 372-383. Peer-reviewed.
Intravenous streptomycin dosing regimen in a patient undergoing hemodialysis: Plasma level monitoring and pharmacokinetic simulation
Chtioui H., Zbinden D., Manuel O., Entenza J., Decosterd L.A., Buclin T., 2013/08. pp. e106 dans 11th Conference of the European Association for Clinical Pharmacology and Therapeutics, Clinical Therapeutics.
 
A pain in the neck.
Puder J., Stadelmann R., Schoettker P., Buclin T., Grouzmann E., 2013. Clinical Chemistry, 59 (8) pp. 1280-1281.
 
A validated assay by liquid chromatography-tandem mass spectrometry for the simultaneous quantification of elvitegravir and rilpivirine in HIV positive patients.
Aouri M., Calmy A., Hirschel B., Telenti A., Buclin T., Cavassini M., Rauch A., Decosterd L.A., 2013. Journal of Mass Spectrometry, 48 (5) pp. 616-625.
 
Authors' response to: Statins in pregnancy: safety and perspectives of therapeutic applications.
Winterfeld U., Allignol A., Panchaud A., Rothuizen L., Merlob P., Cuppers-Maarschalkerweerd B., Vial T., Stephens S., Clementi M., De Santis M. et al., 2013. BJOG, 120 (11) p. 1440.
 
Benchmarking therapeutic drug monitoring software: A review of available computer tools
Fuchs A., Csajka C., Thoma Y., Buclin T., Widmer N., 2013. Clinical Pharmacokinetics, 52 (1) pp. 9-22. Peer-reviewed.
 
Biases on the administered parenteral doses of an experimental drug during phase I clinical trials
Perrottet Ries N., Brunner-Ferber F., Grouzmann E., Spertini F., Biollaz J., Buclin T., Widmer N., 2013. pp. e2-e3 dans 11th Congress of the European Association for Clinical Pharmacology and Therapeutics (EACPT), Clinical Therapeutics. Peer-reviewed.
 
Clinical pharmacokinetics of imatinib and its therapeutic relevance
Widmer N., Gotta V., Haouala A., Blanc J., von Mehren M., Duchosal M., Leyvraz S., Csajka C., Decosterd L.A., Buclin T., 2013. pp. 15-43 dans Akhtari M., Elhemaidi I. (eds.) Imatinib: Chemical structure, pharmacology and adverse effects chap. 2, Nova Science Publishers.
 
EzeCHiel validation: Comparison of gentamicin drug concentration predictions to a reference method (NONMEM)
Fuchs A., Thoma Y., Csajka C., Buclin T., Widmer N., 2013. dans Nano-Tera Annual Plenary Meeting.
 
Free and total plasma levels of lopinavir during pregnancy, at delivery and postpartum: implications for dosage adjustments in pregnant women.
Fayet-Mello A., Buclin T., Guignard N., Cruchon S., Cavassini M., Grawe C., Gremlich E., Popp K.A., Schmid F., Eap C.B. et al., 2013. Antiviral Therapy, 18 (2) pp. 171-182. Peer-reviewed.
Hemodialysis for cefepime intoxication: A case report
Mani L.Y., Kissling S., Burnier M., Buclin T., Renard D., 2013. pp. e24 dans 11th Conference of the European Association for Clinical Pharmacology and Therapeutics, Clinical Therapeutics.
 
Imatinib-induced dose-dependent interstitial lung disease successfully switched to nilotinib: a case report with concentration exposure data.
Dao K., Védy D., Lopez J., Staneczek O., Buclin T., Livio F., 2013. International journal of hematology, 97 (2) pp. 299-300.
 
Multiplex liquid chromatography-tandem mass spectrometry assay for simultaneous therapeutic drug monitoring of ribavirin, boceprevir, and telaprevir.
Aouri M., Moradpour D., Cavassini M., Mercier T., Buclin T., Csajka C., Telenti A., Rauch A., Decosterd L.A., 2013. Antimicrobial Agents and Chemotherapy, 57 (7) pp. 3147-3158. Peer-reviewed.
 
Pharmacogenetics-based population pharmacokinetic analysis of etravirine in HIV-1 infected individuals.
Lubomirov R., Arab-Alameddine M., Rotger M., Fayet-Mello A., Martinez R., Guidi M., di Iulio J., Cavassini M., Günthard H.F., Furrer H. et al., 2013. Pharmacogenetics and Genomics, 23 (1) pp. 9-18. Peer-reviewed.
 
Pharmacokinetic interaction between methotrexate and chloral hydrate.
Dao K., Ivanyuk A., Buclin T., Beck-Popovic M., Diezi M., 2013. Pediatric Blood and Cancer, 60 (3) pp. 518-520.
Population pharmacokinetic study of gentamicin: A retrospective analysis in a large cohort of neonate patients
Fuchs A., Guidi M., Giannoni E., Buclin T., Widmer N., Csajka C., 2013. pp. Abstract 2906 dans 22nd Population Approach Group in Europe (PAGE) Meeting, PAGE. Abstracts of the Annual Meeting of the Population Approach Group in Europe. Peer-reviewed.
Population pharmacokinetics of mefloquine, piperaquine and artemether-lumefantrine in Cambodian and Tanzanian malaria patients.
Staehli Hodel E.M., Guidi M., Zanolari B., Mercier T., Duong S., Kabanywanyi A.M., Ariey F., Buclin T., Beck H.P., Decosterd L.A. et al., 2013. Malaria Journal, 12 p. 235. Peer-reviewed.
 
Prediction of free imatinib concentrations based on total plasma concentrations in patients with gastrointestinal stromal tumours.
Haouala A., Widmer N., Guidi M., Montemurro M., Leyvraz S., Buclin T., Eap C.B., Decosterd L.A., Csajka C., 2013. British Journal of Clinical Pharmacology, 75 (4) pp. 1007-1018. Peer-reviewed.
Pregnancy outcome following maternal exposure to Mirtazapine: Preliminary results of a collaborative ENTIS study.
Winterfeld U., Buclin T., Klinger G., Panchaud A., Stephens S., Arnon J., Malm H., te Winkel B., Clementi M., Pistelli A. et al., 2013. pp. e1-e2 dans 11th Conference of the European Association for Clinical Pharmacology and Therapeutics, Clinical Therapeutics.
 
Pregnancy outcome following maternal exposure to statins: a multicentre prospective study.
Winterfeld U., Allignol A., Panchaud A., Rothuizen L.E., Merlob P., Cuppers-Maarschalkerweerd B., Vial T., Stephens S., Clementi M., De Santis M. et al., 2013. BJOG, 120 (4) pp. 463-471. Peer-reviewed.
 
Prescription du monitoring pratique médicate: de l'empirisme eclairé aux stratégies rationnelles [Prescribing monitoring in clinical practice: from enlightened empiricism to rational strategies].
Buclin T., Herzig L., 2013. Revue Médicale Suisse, 9 (386) pp. 1037-1041.
 
Response to Diaz and de Leon "The Mathematics of Drug Dose Individualization Should be Built With Random Effects Linear Models".
Holford N.H., Buclin T., 2013. Therapeutic Drug Monitoring, 35 (6) pp. 873-874.
Simulation-based systematic review of imatinib population pharmacokinetics and PK-PD relationships in chronic myeloid leukemia (CML) patients
Gotta V., Buclin T., Widmer N., Csajka C., 2013. pp. Abstract 2904 dans 22nd Population Approach Group in Europe (PAGE) Meeting, PAGE. Abstracts of the Annual Meeting of the Population Approach Group in Europe. Peer-reviewed.
Strategies for the development of tdm for targeted anticancer agents
Buclin T., 2013. pp. e113-e114 dans 11th Conference of the European Association for Clinical Pharmacology and Therapeutics, Clinical Therapeutics.
 
Systematic review of population pharmacokinetic analyses of imatinib and relationships with treatment outcomes
Gotta V., Buclin T., Csajka C., Widmer N., 2013. Therapeutic Drug Monitoring, 35 (2) pp. 150-167. Peer-reviewed.
Toxic and drug-induced peripheral neuropathies: updates on causes, mechanisms and management.
Diezi M., Buclin T., Kuntzer T., 2013. Current Opinion in Neurology, 26 (5) pp. 481-488. Peer-reviewed.
Une attente encore trop longue. Du développement à l'utilisation la plus juste des nouveaux traitements.
Buclin T., 2013. Courrier du Médecin Vaudois 6 p. 7.
 
Agents anti-infectieux et fonction réna!e: vers des posologies sur mesure [Antimicrobial agents and renal elimination: towards individual dosage adjustment?].
Willi-Robatel C., Senn L., Livio F., Zanetti G., Marchetti O., Buclin T., 2012. Revue Médicale Suisse, 8 (338) pp. 894-900.
 
Benchmarking therapeutic drug monitoring software: A systematic evaluation of available computer tools
Fuchs A., Csajka C., Thoma Y., Buclin T., Widmer N., 2012. pp. 113S-114S dans 80. Jahresversammlung der Schweizerischen Gesellschaft für Allgemeine Innere Medizin, Swiss Medical Forum. Peer-reviewed.
Benchmarking therapeutic drug monitoring software: A systematic evaluation of available computer tools
Fuchs A., Csajka C., Thoma Y., Buclin T., Widmer N., 2012. p. 2351 dans 21st Population Approach Group in Europe (PAGE) Meeting, Abstracts of the Annual Meeting of the Population Approach Group in Europe. Peer-reviewed.
 
Benchmarking therapeutic drug monitoring software: A systematic evaluation of available computer tools
Fuchs A., Csajka C., Thoma Y., Buclin T., Widmer N., 2012. dans Nano-Tera Annual Plenary Meeting.
Challenging recommended oral and intravenous voriconazole doses for improved efficacy and safety: population pharmacokinetics-based analysis of adult patients with invasive fungal infections.
Pascual A., Csajka C., Buclin T., Bolay S., Bille J., Calandra T., Marchetti O., 2012. Clinical Infectious Diseases, 55 (3) pp. 381-390.
 
Cytogenetic response to imatinib in chronic myeloid leukaemia patients: concentration dependency and associated influences under field-conditions
Gotta V., Bouchet S., Widmer N., Csajka C., Buclin T., Mahon F.-X., Molimard M., 2012. pp. 107S dans 80. Jahresversammlung der Schweizerischen Gesellschaft für Allgemeine Innere Medizin, Swiss Medical Forum. Peer-reviewed.
 
Dosage optimization of treatments using population pharmacokinetic modeling and simulation.
Guidi M., Arab-Alameddine M., Rotger M., Aouri M., Telenti A., Decosterd L.A., Buclin T., Csajka C., Swiss HIV Cohort Study, 2012. Chimia, 66 (5) pp. 291-295. Peer-reviewed.
 
Drug interactions between voriconazole, darunavir/ritonavir and etravirine in an HIV-infected patient with Aspergillus pneumonia.
Aouri M., Decosterd L.A., Buclin T., Hirschel B., Calmy A., Livio F., 2012. AIDS, 26 (6) pp. 776-778.
 
Etude d'inhalation contrôlée chez les fumeurs occasionnels et réguliers de cannabis: comparaison des profils cinétiques des cannabinoïdes et effets comportementaux (O11)
Giroud C., Fabritius M., Battistella G., Fornari E., Lauer E., Dao K., Mall J.-F., Appenzeller M., Annoni J.M., Favrat B. et al., 2012., Société Française de Toxicologie Analytique pp. S1-5/S1-6 dans 20e congrès de la Société Française de Toxicologie Analytique (SFTA) 19-21 septembre 2012, Chambéry, France, Annales de Toxicologie Analytique / Annals of Analytical Toxicology.
 
EzeCHiel: Drug concentration prediction and analysis software
Noverraz B., Stadelmann J., Sambuc L., Gotta V., Fuchs A., Widmer N., Buclin T., Thoma Y., 2012. dans Nano-Tera Annual Plenary Meeting.
 
Impact of tamoxifen dose on tamoxifen and its active metabolites exposure in breast cancer patients: preliminary results from a prospective, open-label trial
Dahmane E., Zaman K., Galmiche Rindisbacher M., Berthod G., Perey L., Bodmer A., Leyvraz S., Eap C., Decosterd L., Buclin T. et al., 2012. pp. 108S dans 80. Jahrestagung der Schweizerischen Gesellschaft für Allgemeine Innere Medizin, Swiss Medical Forum = Forum Médical Suisse.
Late onset tacrolimus-induced life-threatening polyneuropathy in a kidney transplant recipient patient
Renard D., Gauthier T., Venetz J.-P., Buclin T., Kuntzer T., 2012. Clinical Kidney Journal, 5 (4) pp. 323-326. Peer-reviewed.
 
Monitoring drug therapy.
Buclin T., Gotta V., Fuchs A., Widmer N., Aronson J., 2012. British Journal of Clinical Pharmacology, 73 (6) pp. 917-923. Peer-reviewed.
 
Monoamine oxidase A down-regulation contributes to high metanephrine concentration in pheochromocytoma.
Grouzmann E., Matter M., Bilz S., Herren A., Triponez F., Henzen C., Kim K.S., Zulewski H., Buclin T., Brakch N. et al., 2012. Journal of Clinical Endocrinology and Metabolism, 97 (8) pp. 2773-2781.
 
Pharmacokinetic (PK)-based dosage individualization of imatinib: evaluation of efficiency and clinical usefulness
Gotta V., Widmer N., Decosterd L.A., Montemurro M., Leyvraz S., Chalandon Y., Heim D., Gregor M., Benz R., Leoncini-Franscini L. et al., 2012. dans 3rd Symposium of the Swiss Clinical Trial Organisation (SCTO), Personalised Medicine in Clinical Research.
 
Pharmacovigilance [Pharmacovigilance].
Livio F., Renard D., Buclin T., 2012. Revue Médicale Suisse, 8 (324) pp. 116-119.
Pharmacovigilance in pregnancy: adverse drug reactions associated with fetal disorders.
Wettach C., Thomann J., Lambrigger-Steiner C., Buclin T., Desmeules J., von Mandach U., 2012. Journal of Perinatal Medicine, 41 (3) pp. 301-307. Peer-reviewed.
 
Population pharmacokinetic analysis and pharmacogenetics of raltegravir in HIV-positive and healthy individuals.
Arab-Alameddine M., Fayet-Mello A., Lubomirov R., Neely M., di Iulio J., Owen A., Boffito M., Cavassini M., Günthard H.F., Rentsch K. et al., 2012. Antimicrobial Agents and Chemotherapy, 56 (6) pp. 2959-2966.
 
Population pharmacokinetics in chronic myeloid leukaemia patients: observations under field-conditions
Gotta V., Bouchet S., Widmer N., Mahon F.-X., Molimard M., Buclin T., Csajka C., 2012. pp. 111S-112S dans 80. Jahresversammlung der Schweizerischen Gesellschaft für Allgemeine Innere Medizin, Swiss Medical Forum. Peer-reviewed.
Pragmatic approach for interpreting antiretroviral drug concentrations based on a systematic review of population pharmacokinetic studies
Arab-Alameddine M., Buclin T., Guidi M., Widmer N., Decosterd L.A., Csajka C., 2012. pp. Abstr 2441 dans 21st Population Approach Group in Europe (PAGE) meeting, Abstracts of the Annual Meeting of the Population Approach Group in Europe. Peer-reviewed.
 
Pregnancy outcome following exposure to topical retinoids: a multicenter prospective study.
Panchaud A., Csajka C., Merlob P., Schaefer C., Berlin M., De Santis M., Vial T., Ieri A., Malm H., Eleftheriou G. et al., 2012. Journal of Clinical Pharmacology, 52 (12) pp. 1844-1851. Peer-reviewed.
 
Prevalence and determinants of QT interval prolongation in medical inpatients.
Pasquier M., Pantet O., Hugli O., Pruvot E., Buclin T., Waeber G., Aujesky D., 2012. Internal Medicine Journal, 42 (8) pp. 933-940.
 
Prevalence, incidence and indications of hypno-sedative treatments in hospitalized patients aged 75 and older
Von Rohr T.R., Rochat S., Monod S., Buela C., Buclin T., Renard D., Csajka C., 2012. p. 228 dans 40th International Symposium on Clinical Pharmacy (ESCP), Clinical Pharmacy: Connecting Care and Outcomes, International Journal of Clinical Pharmacy.
Probability of achieving optimal molecular response to imatinib in chronic myeloid leukemia (CML) patients: Pharmacokinetic/Pharmacodynamic (PK/PD) relationships observed under field-conditions
Gotta V., Bouchet S., Widmer N., Mahon F.X., Molimard M., Buclin T., Csajka C., 2012. p. 2504 dans 21st Population Approach Group in Europe (PAGE) Meeting, Abstracts of the Annual Meeting of the Population Approach Group in Europe. Peer-reviewed.
 
Safe and effective variability-a criterion for dose individualization.
Holford N.H., Buclin T., 2012. Therapeutic Drug Monitoring, 34 (5) pp. 565-568. Peer-reviewed.
 
Syndrome sérotoninergique: mise au point et revue des cas annoncés en Suisse [Serotonin syndrome: review and case series from the Swiss pharmacovigilance system].
Chassot M., Munz T., Livio F., Buclin T., 2012. Revue Médicale Suisse, 8 (360) pp. 2086-2090.
 
Therapeutic drug monitoring of imatinib: Bayesian and alternative methods to predict trough levels
Gotta V., Widmer N., Montemurro M., Leyvraz S., Haouala A., Decosterd L.A., Csajka C., Buclin T., 2012. Clinical Pharmacokinetics, 51 (3) pp. 187-201. Peer-reviewed.
 
Therapeutic drug monitoring of targeted anticancer therapy. Tyrosine kinase inhibitors and selective estrogen receptor modulators: A clinical pharmacology laboratory perspective
Decosterd L.A., Dahmane E., Neeman M., Buclin T., Csajka C., Haouala A., Widmer N., 2012. pp. 197-250 dans Xu Q.A, Madden T.L. (eds.) LC-MS in drug bioanalysis chap. 9, Springer.
Utilisation des laxatifs à l'Hôpital
Dao Kim, Renard Delphine, Livio Françoise, Buclin Thierry, De Giorgi I, 2012. GSASA Journal 26 pp. 27-31.
 
Vancomycin exposure from active calcium sulfate bone filler
Livio F., Guidi M., Wahl P., Gautier E., Prod'Hom G., Buclin T., Csajka T., 2012. pp. 112S dans 80. Jahrestagung der Schweizerischen Gesellschaft für Allgemeine Innere Medizin, Swiss Medical Forum = Forum Médical Suisse.
Traitement et prophylaxie de la Maladie ThromboEmbolique Veineuse (MTEV)
Centre hospitalier universitaire vaudois, Policlinique médicale universitaire (Lausanne) , 2011/05. 2 p..
 
Effets du cannabis sur les fumeurs occasionnels
Giroud C., Battistella G., Thomas A., Maeder P., Mall J.F., Annoni J.M., Appenzeller M., Buclin T., Staub C., Mangin P. et al., 2011/03., Société Française de Toxicologie Analytique (SFTA) pp. S1-8 dans Société Française de Toxicologie Analytique (SFTA) (eds.) Annales de toxicologie analytique, EDP Sciences.
 
Evaluation of risk perception related to drug use during pregnancy: a swiss survey
Jaquet A., Winterfeld U, Meyer Y., Buclin T., Csajka C., Panchaud A., 2011/02. p. 260 dans Reproductive Toxicology. Peer-reviewed.
Additifs alimentaires et troubles de l’attention/hyperactivité chez l’enfant
Diezi Manuel, Buclin Thierry, Diezi Jacques, 2011. Paediatrica, 22 (5) pp. 12-15.
 
Antiretroviral drug toxicity in relation to pharmacokinetics, metabolic profile and pharmacogenetics.
Arab-Alameddine M., Décosterd L.A., Buclin T., Telenti A., Csajka C., 2011. Expert Opinion On Drug Metabolism and Toxicology, 7 (5) pp. 609-622.
Cell disposition of raltegravir and newer antiretrovirals in HIV-infected patients: high inter-individual variability in raltegravir cellular penetration.
Fayet Mello A., Buclin T., Franc C., Colombo S., Cruchon S., Guignard N., Biollaz J., Telenti A., Decosterd L.A., Cavassini M., 2011. Journal of Antimicrobial Chemotherapy, 66 (7) pp. 1573-1581.
Development and Validation of Decision Rules to Guide Frequency of Monitoring CD4 Cell Count in HIV-1 Infection before Starting Antiretroviral Therapy.
Buclin T., Telenti A., Perera R., Csajka C., Furrer H., Aronson J.K., Glasziou P.P., 2011. Plos One, 6 (4) pp. e18578.
 
Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib.
Haouala A., Widmer N., Duchosal M.A., Montemurro M., Buclin T., Decosterd L.A., 2011. Blood, 117 (8) pp. e75-e87. Peer-reviewed.
 
Evaluation of risk perception related to drug use during pregnancy: a Swiss survey
Jaquet A., Winterfeld U., Meyer Y., Buclin T., Csajka C., Panchaud A., 2011. pp. 422-423 dans 39th ESCP European Symposium on Clinical Pharmacy and 13th SFPC Congress: Clinical Pharmacy at the Front Line of Innovations, International Journal of Clinical Pharmacy. Peer-reviewed.
 
How quickly should we titrate antihypertensive medication? Systematic review modelling blood pressure response from trial data.
Lasserson D.S., Buclin T., Glasziou P., 2011. Heart, 97 (21) pp. 1771-1775.
 
How to Improve the Use of Proton Pump Inhibitors
Hodel M., Pauchet A., Buclin T., Mottet C., Gloor S., Guyot C., Biolat J., Chtioui H., Genne D., 2011. p. 164 dans 10th Congress of the European Association for Clinical Pharmacology and Therapeutics, Basic & Clinical Pharmacology & Toxicology. Peer-reviewed.
 
Improvement of therapeutic drug monitoring of imatinib by Bayesian prediction of trough levels. Personalized drug dosage
Gotta V., Widmer N., Montemurro M., Leyvraz S., Haouala A., Decosterd L.A., Csajka C., Buclin T., 2011. p. 478 dans 12th International Congress of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT), Therapeutic Drug Monitoring. Peer-reviewed.
 
Need of reduced and harmonized bureaucracy in multi-centre clinical research - a case-report from a Swiss trial
Gotta V., Vallotton L., Widmer N., Buclin T., 2011. p. 7 dans 2011 Joint Annual Meeting of the German, Swiss, and Austrian Societies for Clinical Pharmacology and Toxicology, British Journal of Clinical Pharmacology. Peer-reviewed.
 
P-glycoprotein modulation by valspodar and cyclosporin does not increase tumor uptake of doxorubicin administered via isolated lung perfusion to rats bearing sarcoma lung metastases.
Kuemmerle A., Yan H., Krueger T., Buclin T., Braissant O., Henry H., Ris H.B., Decosterd L.A., 2011. Anticancer Research, 31 (6) pp. 2121-2128.
 
Personalized drug dosage: Monitoring of imatinib concentration with a Bayesian interpretation tool
Gotta V., Widmer N., Montemurro M., Leyvraz S., Haouala A., Decosterd L.A., Csajka C., Buclin T., 2011. dans Nano-Tera Annual Plenary Meeting.
 
Pharmacovigilance [Pharmacovigilance update].
Livio F., Biollaz J., Buclin T., 2011. Revue Médicale Suisse, 7 (277) pp. 71-74.
 
Pregnancy Outcome Following Maternal Exposure To Statins: A Multicenter Prospective Study
Winterfeld U., Panchaud A., Merlob P., Rothuizen L., Cuppers-Maarschalkerweerd B., Vial T., Stephens S., Clementi M., De Santis M., Pistelli A. et al., 2011. p. 142 dans 10th Congress of the European Association for Clinical Pharmacology and Therapeutics, Basic & Clinical Pharmacology & Toxicology. Peer-reviewed.
 
Pregnancy outcome following maternal exposure to statins: a multicenter prospective study
Winterfeld U., Panchaud A., Merlob P., Rothuizen L., Cuppers-Maarschalkerweerd B., Vial T., Stephens S., Clementi M., De Santis M., Pistelli A. et al., 2011. p. 32 dans 2011 Joint Annual Meeting of the German, Swiss, and Austrian Societies for Clinical Pharmacology and Toxicology, British Journal of Clinical Pharmacology. Peer-reviewed.
 
Substance P-induced skin inflammation is not modulated by a single dose of sitagliptin in human volunteers.
Grouzmann E., Bigliardi P., Appenzeller M., Pannatier A., Buclin T., 2011. Biological Chemistry, 392 (3) pp. 217-221.
 
Successful efavirenz dose reduction guided by therapeutic drug monitoring.
Fayet Mello A., Buclin T., Decosterd L.A., Delhumeau C., di Iulio J., Fleurent A., Schneider M.P., Cavassini M., Telenti A., Hirschel B. et al., 2011. Antiviral Therapy, 16 (2) pp. 189-197.
 
Systemic exposure to tobramycin after local antibiotic treatment with calcium sulphate as carrier material.
Wahl P., Livio F., Jacobi M., Gautier E., Buclin T., 2011. Archives of Orthopaedic and Trauma Surgery, 131 (5) pp. 657-662.
 
The Authors' reply to "Mistaken conclusion"
Lasserson D.S., Buclin T., Glasziou P., 2011. Heart, 97 (24) pp. 2091-2092.
 
Traitements de fer: preuves de l'efficacité et bonne pratique clinique [Iron therapy: proof of efficacy and good clinical practice].
Renard D., Favrat B., Livio F., Buclin T., 2011. Revue Médicale Suisse, 7 (292) pp. 923-927.
 
Who is in charge of assessing therapeutic drug monitoring? The case of imatinib.
Buclin T., Widmer N., Biollaz J., Decosterd L.A., 2011. Lancet Oncology, 12 (1) pp. 9-11. Peer-reviewed.
 
ADME pharmacogenetics: investigation of the pharmacokinetics of the antiretroviral agent lopinavir coformulated with ritonavir.
Lubomirov R., di Iulio J., Fayet A., Colombo S., Martinez R., Marzolini C., Furrer H., Vernazza P., Calmy A., Cavassini M. et al., 2010. Pharmacogenetics and Genomics, 20 (4) pp. 217-230.
 
An ultra performance liquid chromatography-tandem MS assay for tamoxifen metabolites profiling in plasma: first evidence of 4'-hydroxylated metabolites in breast cancer patients.
Dahmane E., Mercier T., Zanolari B., Cruchon S., Guignard N., Buclin T., Leyvraz S., Zaman K., Csajka C., Decosterd L.A., 2010. Journal of Chromatography. B, Analytical Technologies In the Biomedical and Life Sciences, 878 (32) pp. 3402-3414.
 
Cannabinoids time-profiles, subjective and clinical effects, simulating driving capability after smoking a joint made of neat cannabis containing 11% THC
Giroud C., Thomas A., Battistella G., Maeder P., Mall J.F., Annoni J.M., Appenzeller M., Buclin T., Staub C., Mangin P. et al., 2010. dans SOFT 2010, Annual Meeting of the Society of Forensic Toxicologists. Peer-reviewed.
 
Cardiovascular drug interactions with tyrosine kinase inhibitors
Haouala A., Widmer N., Montemurro M., Buclin T., Decosterd L., 2010. Cardiovascular Medicine, 13 (5) pp. 147-154. Peer-reviewed.
 
Determination of oseltamivir and oseltamivir carboxylate in human plasma by liquid chromatography-tandem mass spectrometry
Aouri M., Zanolari B., Meylan P., Ivanyuk A., Buclin T., Decosterd L.A., Widmer N., 2010. pp. 25S dans Réunion annuelle Société Suisse de Médecine Intensive, Société Suisse d'Infectiologie, Société Suisse d'Hygiène Hospitalière, Société Suisse de Pharmacologie et Toxicologie Cliniques, Communauté Suisse d'intérêts pour soins intensifs, Invité: Société Suisse de Transplantation, Swiss Medical Forum = Forum Médical Suisse. Peer-reviewed.
 
Diagnostic accuracy of free and total metanephrines in plasma and fractionated metanephrines in urine of patients with pheochromocytoma.
Grouzmann E., Drouard-Troalen L., Baudin E., Plouin P.F., Muller B., Grand D., Buclin T., 2010. European Journal of Endocrinology / European Federation of Endocrine Societies, 162 (5) pp. 951-960.
 
Evaluation of the impact of a therapeutic drug monitoring program in a Swiss University Hospital
Fernandez S., Widmer N., Buclin T., Biollaz J., Csajka C., 2010. pp. 283-284 dans ESCP-GSASA, 38th Symposium on Clinical Pharmacy, 30 years of clinical pharmacy : a bright future ahead, Pharmacy World and Science. Peer-reviewed.
 
Feasibility of Therapeutic Drug Monitoring (TDM) for Imatinib: Preliminary considerations on the dosage adjustment approach for CML patients enrolled in the Imatinib Concentration Monitoring (I-COME) study
Gotta V., Widmer N., Decosterd L.A., Csajka C., Duchosal M.A., Chalandon Y., Heim D., Gregor M., Buclin T., 2010. pp. 90S dans 78. Jahresversammlung der Schweizerischen Gesellschaft für Innere Medizin, Swiss Medical Forum = Forum Médical Suisse. Peer-reviewed.
 
Ganciclovir exposure under a 450mg daily dosage of valganciclovir for cytomegalovirus prevention in kidney transplantation: a prospective study.
Manuel O., Pascual M., Perrottet N., Lamoth F., Venetz J.P., Decosterd L.A., Buclin T., Meylan P.R., 2010. Clinical Transplantation, 24 (6) pp. 794-800.
 
Hypertension. Angio-oedème sous inhibition de l'enzyme de conversion de l'angiotensine et de la dipeptidyl-peptidase-4 [Angioedema during ACE and DPP-4 inhibition]
Waeber B., Buclin T., Grouzmann E., 2010. Revue Médicale Suisse, 6 (231) pp. 28-31.
Imatinib plasma levels: correlation with clinical benefit in GIST patients.
Widmer N., Decosterd L.A., Csajka C., Montemurro M., Haouala A., Leyvraz S., Buclin T., 2010. British Journal of Cancer, 102 (7) pp. 1198-1199. Peer-reviewed.
Impact of cannabis inhalation on driving skills in occasional smokers
Thomas A., Battistella G., Maeder P., Mall J.F., Annoni J.M., Chtioui H., Appenzeller M., Buclin T., Staub C., Mangin P. et al., 2010. dans Tri-Annual Meeting of the International Council on Alcohol, Drugs and Traffic Safety.
 
Mapping the impact of cannabis on driving skills in occasional smokers. 84 MT-PM cognition and attention. Executive Function
Battistella G., Maeder P., Thomas A., Mall J.F., Annoni J.M., Appenzeller M., Favrat B., Chtioui H., Buclin T., Staub C. et al., 2010. dans OHBM 2010, 16th Annual Meeting of the Organization for Human Brain Mapping.
 
Oseltamivir in seasonal, avian H5N1 and pandemic 2009 A/H1N1 influenza: pharmacokinetic and pharmacodynamic characteristics.
Widmer N., Meylan P., Ivanyuk A., Aouri M., Decosterd L.A., Buclin T., 2010. Clinical Pharmacokinetics, 49 (11) pp. 741-765. Peer-reviewed.
 
Pharmacovigilance update [Pharmacovigilance update]
Livio F., Ivanyuk A., Biollaz J., Rothuizen L., Buclin T., 2010. Revue Médicale Suisse, 6 (232) pp. 128-131.
 
Pregnancy outcome after maternal exposure to statins: a multicenter prospective study
Winterfeld U., Panchaud A., Merlob P., Cuppers-Maarschalkerweerd B., Vial T., Stephens S., Clementi M., De Santis M., Pistelli A., Berlin M. et al., 2010. dans 21st Annual Meeting of the European Network Teratogen Information Services (ENTIS).
Prospective assessment of CYP2D6 by genotyping, phenotyping and measurement of tamoxifen, PD 05-09 4-hydroxy-tamoxifen and endoxifen in breast cancer patients treated with tamoxifen.
Zaman K., Dahmane E., Perey L., Buclin T., Berthod G., Bodmer A., Galmiche M., Leyvraz S., Eap C., Csajka C. et al., 2010. dans 33rd Annual San Antonio Breast Cancer Symposium.
 
Rapid occurrence of depression following addition of sodium oxybate to modafinil.
Rossetti A.O., Heinzer R.C., Tafti M., Buclin T., 2010. Sleep Medicine, 11 (5) pp. 500-501. Peer-reviewed.
 
siRNA-Mediated Knock-Down of P-Glycoprotein Expression Reveals Distinct Cellular Disposition of Anticancer Tyrosine Kinases Inhibitors.
Haouala A., Rumpold H., Untergasser G., Buclin T., Ris H.B., Widmer N., Decosterd L.A., 2010. Drug Metabolism Letters, 4 (2) pp. 114-119. Peer-reviewed.
 
Statines et effets indésirables musculaires [Statins and muscular side-effects]
Brosteaux C., Ruiz J., Buclin T., Kuntzer T., Rodondi N., 2010. Revue Médicale Suisse, 6 (239) pp. 510-517. Peer-reviewed.
Suivi thérapeutique de l'imatinib
Gotta V., Widmer N., Decosterd L.A., Csajka C., Duchosal M.A., Chalandon Y., Heim D., Gregor M., Buclin T., 2010. Forum Medical Suisse, 10 (23) pp. 403-406. Peer-reviewed.
 
Therapeutic Drug Monitoring (TDM) of Imatinib: Effectiveness of Bayesian dose adjustment for CML patients enrolled in the Imatinib Concentration Monitoring (I-COME) study
Gotta V., Widmer N., Decosterd L.A., Csajka C., Duchosal M.A., Chalandon Y., Heim D., Gregor M., Buclin T., 2010. pp. 28S dans Réunion annuelle Société Suisse de Médecine Intensive, Société Suisse d'Infectiologie, Société Suisse d'Hygiène Hospitalière, Société Suisse de Pharmacologie et Toxicologie Cliniques, Communauté Suisse d'intérêts pour soins intensifs, Invité: Société Suisse de Transplantation, Swiss Medical Forum = Forum Médical Suisse. Peer-reviewed.
Variable viral clearance despite adequate ganciclovir plasma levels during valganciclovir treatment for cytomegalovirus disease in D+/R- transplant recipients.
Perrottet Nancy, Manuel Oriol, Lamoth Frederic, Venetz Jean-Pierre, Sahli Roland, Decosterd Laurent A., Buclin Thierry, Pascual Manuel, Meylan Pascal, 2010. BMC Infectious Diseases, 10 p. 2.
Residual antimalarials in malaria patients from Tanzania--implications on drug efficacy assessment and spread of parasite resistance.
Hodel E.M., Kabanywanyi A.M., Malila A., Zanolari B., Mercier T., Beck H.P., Buclin T., Olliaro P., Decosterd L.A., Genton B., 2009/12/14. PloS one, 4 (12) pp. e8184. Peer-reviewed.
Tamoxifen metabolism and the impact of Tamoxifen dose on the level of the active metabolites in endocrine sensitive breast cancer patients
Dahmane Elyes, Csajka Chantal, Decosterd Laurent, Mercier Thomas, Zanolari Boris, Eap Chin, Buclin Thierry, Galmiche Marie, Zaman Khalil, 2009/09. dans ''Frontiers in drug discovery and development'' : 24ème séminaire, 3ème cycle, en sciences pharmaceutiques.
 
Acute effects of cannabis smoking on skills related to driving in occasional and heavy smokers
Giroud C., Battistella G., Buclin T., Mall JF., Thomas P., Favrat B., Mangin P., Maeder P., Fornari E., 2009/03. dans Lausanne, CHUV, CIBM-MR Research Meeting. March 16th. Oral presentation.
 
"Iatrogenicity cascade": doing harm by treating harm?
Wagner C.C., Biollaz J., Zeitlinger M., Buclin T., 2009. Wiener Medizinische Wochenschrift, 159 (1-2) pp. 53-57.
 
A LC-tandem MS assay for the simultaneous measurement of new antiretroviral agents: Raltegravir, maraviroc, darunavir, and etravirine.
Fayet A., Béguin A., Zanolari B., Cruchon S., Guignard N., Telenti A., Cavassini M., Günthard H.F., Buclin T., Biollaz J. et al., 2009. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences, 877 (11-12) pp. 1057-1069.
A phase I pharmacokinetic study of hypoxic abdominal stop-flow perfusion with gemcitabine in patients with advanced pancreatic cancer and refractory malignant ascites
Kuemmerle A., Decosterd L. A., Buclin T., Liénard D., Stupp R., Chassot P. G., Mosimann F., Lejeune F., 2009. Cancer Chemotherapy and Pharmacology, 63 (2) pp. 331-341. Peer-reviewed.
 
Acute Effects of Cannabis Smoking on Skills Related to Driving : an fMRI Study
Fornari E., Maeder P., Chtioui H., Thomas A., Appenzeller M., Favrat B, Buclin T., Staub C., Mangin P., Giroud C., 2009. pp. S179 dans OHBM 2009, 15th Annual Meeting of the Organization for Human Brain Mapping, NeuroImage. Peer-reviewed.
 
Adaptation of clinical practice guidelines on major depressive disorders in the general hospital: an update.
Voellinger R., Berney A., Burnand B., Stiefel F., Depression Development Group, 2009. Journal of Psychosomatic Research, 66 (4) pp. 353-354. Peer-reviewed.
 
Angiotensin-converting enzyme and dipeptidyl peptidase IV inhibitors: an increased risk of angioedema.
Grouzmann E., Livio F., Buclin T., 2009. Hypertension, 54 (3) pp. 468-470. Peer-reviewed.
Blood cannabinoids levels and effects on cognitive performance and behavior as a function of joint smoking procedure and inhalation technique
Giroud Christian, Favrat Bernard, Thomas Aurélien, Battistella Giovanni, Mall Jean-Frédéric, Appenzeller Monique, Lauer Estelle, Buclin Thierry, Fornari Eleonora, Maeder Philippe et al., 2009. pp. S12 dans SOFT 2009 Annual Meeting, Society of Forensic Toxicologists. Peer-reviewed.
Cannabis intoxication with perceptual disturbances under clinical setting : O44
Giroud Christian, Thomas Aurélien, Mall Jean-Frédéric, Favrat Bernard, Appenzeller Monique, Buclin Thierry, Fornari Eleonara, Battistella Giovanni, Maeder Philippe, Staub Christian et al., 2009. p. 22 dans 47th Annual Meeting of the International Association of Forensic Toxicologists, Annales de Toxicologie Analytique. Peer-reviewed.
Partagez:
Unicentre - CH-1015 Lausanne
Suisse
Tél. +41 21 692 11 11
Fax. +41 21 692 26 15
Swiss University